VolitionRx Limited (VNRX:NYSEMKT) closed at $0.174 on October 19, 2026, down 3.50% on the day. The stock trades 98.2% below its 52-week high of $9.60 and 3.7% above its 52-week low of $0.168. Over the past year, it lost 59.1%. VolitionRx Limited is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
In 251 trading sessions since October 17, 2025, VNRX closed higher on 67 days (27%). Its best day was August 27, 2026 (+47.06%) and its worst was June 8, 2026 (-22.35%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 9 times.
VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants. The company also develops blood assays in the Nu.Q-M family to detect nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; blood assays in the Nu.Q-A family to detect nucleosome-protein adducts; and a Nu.Q-T assay to detect cancer by detecting total blood nucleosome levels. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.
Find more stocks like VNRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.